Exemestane vs. tamoxifen after 2-3 years' tamoxifen



Switching to exemestane after 2 to 3 years of treatment with tamoxifen improves disease-free and overall survival in postmenopausal women with estrogen-receptor–positive early breast cancer, according to the results of a randomized, controlled trial from Europe.

Researchers included almost 5,000 women who had unilateral invasive disease but who were disease-free after 2 to 3 years of treatment with tamoxifen. Half the women were then switched to the aromatase inhibitor exemestane, while the other half continued taking tamoxifen for the remainder of 5 years.

After a median follow-up of 4.5 years, the unadjusted hazard ratio was 0.76 (95% CI, 0.66–0.88, P=0.0001) in favor of exemestane. The absolute benefit by the end of treatment was 3.3% (95% CI, 1.6–4.9). In terms of number of deaths, 222 occurred in the exemestane group versus 261 in the tamoxifen group.

Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559-570.

Related Videos
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Deciding the best treatment for uterine fibroids | Image Credit: jeffersonhealth.org.
Clinical pearls of pediatric dermatology | Image Credit: profiles.ucsf.edu
Approaching inflammatory vulvovaginal diseases | Image Credit: profiles.ucsf.edu.
Related Content
© 2024 MJH Life Sciences

All rights reserved.